Diagnosis and Management of Bartter Syndrome (Types 1 & 2)

Pathophysiology

Bartter syndrome is an inherited salt‑losing tubulopathy of the thick ascending limb that produces hypokalemic metabolic alkalosis due to impaired Na⁺/K⁺/2Cl⁻ reabsorption【2】【3】.
The disease characteristically features normotensive hyperreninemic hyperaldosteronism, although hypertension may develop paradoxically, especially when secondary hyperparathyroidism is present【2】.
Hypercalciuria leads to medullary nephrocalcinosis in Types 1 and 2, distinguishing these genotypes from other tubulopathies【1】【3】.
Chronic renal salt and calcium loss triggers secondary hyperparathyroidism (elevated PTH with normal serum calcium) as a compensatory response【1】.

The combination of elevated PTH, normal calcium, hypokalemia, hypertension (or normotension), and medullary nephrocalcinosis strongly points to Bartter syndrome Types 1 or 2【1】【2】【3】.

Serum electrolytes: low potassium, normal calcium, possible low magnesium【1】【2】.
Arterial blood gas: metabolic alkalosis expected【2】【3】.
Renin and aldosterone: both elevated, reflecting secondary hyperaldosteronism【2】【3】.
Fractional excretion of chloride: typically > 0.5% in Bartter syndrome【3】【10】.
24‑hour urinary calcium‑creatinine ratio: demonstrates hypercalciuria in Types 1 and 2【1】【3】.
Renal function tests (creatinine, eGFR) to assess baseline kidney status【1】.

Renal ultrasound confirms the presence of medullary nephrocalcinosis【1】【3】.
CT scan provides a more precise assessment of calcifications but carries radiation exposure【1】.

A targeted gene panel is recommended for definitive diagnosis, with analytical sensitivity of 90–100 %【1】.
Priority genes: SLC12A1 (Type 1), KCNJ1 (Type 2), and CLCNKB (Type 3)【1】【2】.

Primary hyperparathyroidism is excluded because it presents with hypercalcemia, not normal calcium【6】【4】【7】.
Dent disease (CLCN5 mutation) shows hypercalciuria and nephrocalcinosis but lacks the characteristic hypokalemic metabolic alkalosis【4】【9】.
Hereditary hypophosphatemic rickets with hypercalciuria (SLC34A3 mutation) features hypophosphatemia rather than the electrolyte profile of Bartter syndrome【4】【9】.
Distal renal tubular acidosis produces metabolic acidosis, not alkalosis【4】【8】.
The presence of hypokalemia with metabolic alkalosis therefore favors Bartter syndrome over these alternatives【1】【2】【3】.

Do not diagnose primary hyperparathyroidism based solely on elevated PTH; normal calcium mandates evaluation for secondary causes【4】【7】.
Exclude confounders before confirming the diagnosis: vitamin D deficiency, reduced GFR, and medications such as thiazide diuretics, loop diuretics, or lithium【4】【8】.
Diuretic challenge tests (e.g., furosemide or thiazide) are obsolete when genetic testing is available and pose a risk of severe volume depletion【3】【10】.

Potassium supplementation combined with potassium‑sparing diuretics (spironolactone, amiloride) to correct hypokalemia【4】.
NSAIDs (e.g., indomethacin) to attenuate prostaglandin‑mediated renal losses【1】.
Salt supplementation to offset renal salt wasting【10】.
Ongoing monitoring of nephrocalcinosis progression and surveillance for chronic kidney disease risk【1】.
Secondary hyperparathyroidism generally does not require specific therapy beyond correction of the underlying tubulopathy【4】【5】.